Introduction
Many human enzymes incorporate or use zinc (Zn 2ϩ ) as a cofactor to catalyze key biochemical reactions. A key role for the metal emerged with discovery of chelatable Zn 2ϩ localization in synaptic vesicles in the brain (Frederickson, 1989; Danscher, 1996) . Zn 2ϩ is present in high level in synaptic vesicles of glumatergic terminals, including hippocampal mossy fibers. It is released during neuronal activity, and its uptake and loading into synaptic vesicle are regulated by Zn 2ϩ transporter ZnT3 (Assaf and Cung, 1984; Cole et al., 1999; Molnár and Nadler, 2001 ). Zn 2ϩ has been shown to modulate certain ion channels and ligand-gated receptors (Harrison and Gibbons, 1994) . Zn 2ϩ is abundant within hippocampal mossy fibers that project from the dentate gyrus to the CA3 (Frederickson et al., 1983) and can be visualized by Timm's staining of the hippocampus (Kay, 2003) . Thus, Zn 2ϩ is suggested to play an important modulatory role in epilepsy (Coulter, 2000) , and Zn 2ϩ -abundant mossy fiber sprouting is a classical morphological index of limbic epileptogenesis (Cavazos et al., 1991) . Zn 2ϩ negatively modulates GABAergic inhibition at
Significance Statement
Zn 2ϩ is most abundant in the synaptic vesicles of hippocampal mossy fibers. Zn 2ϩ release occurs with neuronal excitation, including seizure events, and exerts powerful excitability effects in the hippocampus circuits. Zn 2ϩ inhibits synaptic GABA A receptors, but its interaction is less well appreciated at the extrasynaptic receptors, which respond sensitively to endogenous neurosteroids. Here, we describe selective functional blockade by Zn 2ϩ of neurosteroid-sensitive, extrasynaptic GABA A receptors in the mouse hippocampus dentate gyrus, a key region associated with epilepsy and memory disorders. By demonstrating that extracellular Zn 2ϩ prevents neurosteroid augmentation of tonic current and protection against limbic seizures, our findings provide novel implications of this potential antagonistic interaction in a variety of neurological conditions. mossy fiber synaptic varicosities that release GABA (Ruiz et al., 2004; Bitanihirwe and Cunningham, 2009) . Excessive release of Zn 2ϩ has been reported in epilepsy (Takeda et al., 1999) , and it can elicit excitatory and proconvulsant effects (Foresti et al., 2008) . Zn 2ϩ is a GABA A receptor antagonist and displays differential sensitivities at two receptor subtypes (Smart et al., 1991; Stó rustovu and Ebert, 2006) . In the hippocampus dentate gyrus, ␥-containing receptors are located synaptically and produce phasic currents. Dentate gyrus granule cells (DGGCs) have high expression of extrasynaptic, ␦-containing receptors responsible for continuous tonic inhibition (Glykys et al., 2008) . Synaptic and extrasynaptic receptors are distinct in GABA affinity and efficacy, channel kinetics, and pharmacological sensitivity to allosteric modulators, such as neurosteroids (Reddy, 2011; Wu et al., 2013; Carver et al., 2014) . Three discrete binding sites contribute to Zn 2ϩ inhibition, including one site within the channel pore and two at the external amino terminus of the ␣-␤ interfaces; the inclusion of the ␥-subunit disrupts two of the sites, resulting in reduction in sensitivity (Hosie et al., 2003) . Although the ␦-containing receptors are more sensitive to Zn 2ϩ block than ␥-containing receptors (Mangan et al., 2005) , the ability of Zn 2ϩ to modify extrasynaptic ␦GABA A receptors is poorly understood.
Neurosteroids, such as allopregnanolone (AP), are positive allosteric modulators of synaptic and extrasynaptic GABA A receptors and exhibit a greater potency for extrasynaptic ␦-containing receptors (Spigelman et al., 2003; Stell et al., 2003; Reddy and Jian, 2010) . AP potentiates tonic current in DGGCs and provides robust protection against a variety of seizures and status epilepticus (Carver et al., 2014; Reddy and Estes, 2016) . Zn 2ϩ and neurosteroids have preferential affinity for ␦-containing receptors Reddy, 2013, 2016) . However, the physiological interaction between Zn 2ϩ and neurosteroids at extrasynaptic GABA A receptors remains unclear. We hypothesized that extracellular Zn 2ϩ prevents neurosteroid activation of extrasynaptic ␦GABA A receptor-mediated tonic inhibition and thereby impairs their ability to promote neuroprotection and seizure suppression. In this study, we tested this hypothesis by directly investigating Zn 2ϩ blockade of extrasynaptic ␦GABA A receptor function using a combination of in vitro and in vivo electrophysiological techniques. Our results show that Zn 2ϩ selectively inhibits extrasynaptic ␦GABA A receptors and thereby totally prevents AP activation of tonic inhibition and seizure protection. These results highlight the potential role of Zn 2ϩ in modulating GABAergic tonic inhibition in the hippocampus.
Materials and Methods
Animals. Adult male mice of 2-3 months age, maintained on hybrid C57BL/6 -129SV background, were used for the study. Wild-type and GABA A receptor ␦-subunit knock-out (Gabrd Ϫ/Ϫ , ␦KO) mice were used for experiments. All animal procedures were performed in a protocol approved by the university's Institutional Animal Care and Use Committee.
Hippocampal slice electrophysiology. Transverse slices (300 m) of hippocampus were prepared from mice using standard technique, as reported previously (Carver et al., 2014) . Mice were anesthetized with isoflurane, and brains were excised and placed in 3.5°C aCSF that composed of the following (in mM): 126 NaCl, 3 KCl, 0.5 CaCl 2 , 5 MgCl 2 , 26 NaHCO 3 , 1.25 NaH 2 PO 4 , 11 glucose, 0.3 kynurenic acid, pH adjusted to 7.35-7.40, with 95% O 2-5% CO 2 , 305-315 mOsm/kg. Slices were cut with a vibratome (model 1500 with 900 Refrigeration System, Leica Microsystems). Hippocampal slices were maintained in oxygenated aCSF at 28°C for 60 min, and experiments were performed at 23°C. Neurons were visually identified with an Olympus BX51 microscope equipped with a 40ϫ water-immersion objective, infrared-differential interference contrast optics and camera. Recordings in hippocampus slice were performed in whole-cell patch-clamp configuration as described previously (Carver et al., 2014) . Currents were recorded using an Axopatch 200B amplifier (Molecular Devices). Membrane capacitance, series resistance, and input resistance were monitored by applying 5 mV (100 ms) depolarizing voltage step from holding potential of Ϫ65 mV. Signals were low-pass filtered at 2 kHz and digitized at 10 kHz with Digidata 1440A system. Tonic current and miniature inhibitory postsynaptic currents (mIPSCs) of GABA A receptors were recorded in the presence of TTX (0.5 M, Na ϩ channel blocker, and inhibition of action potential-evoked neurotransmitter release), APV (40 M, NMDA channel blocker), and DNQX (10 M, non-NMDA glutamate receptor blocker). The competitive antagonist gabazine (SR-95531, GBZ, 50 M) was added to perfusion at the conclusion of recordings to confirm block of GABAergic currents. Drugs were delivered to the bath chamber using a multichannel perfusion system (Automate Scientific).
Off-line analysis was performed with pClamp software, as described previously (Carver et al., 2014) . Averaged tonic current shift and rootmean-square (RMS) noise amplitude were measured. GABA A receptor I tonic (tonic current) was expressed as the difference in holding current before and after application of gabazine (50 M) or Zn 2ϩ (1-1000 M). I tonic was measured and averaged in 100 ms each epoch with 1 s interval between 30 epochs. I RMS noise conductance was measured in 50 ms each epoch with 500 ms interval between 30 epochs during drug application. Changes in I tonic or I RMS are expressed in pA of current. For concentration comparisons, currents were normalized to membrane capacitance (pA/pF) as I tonic density. Synaptic currents were recorded and analyzed as previously described (Carver et al., 2014) . The amplitude and decay time constants of mIPSCs were measured using MiniAnalysis software (Synaptosoft). Nonoverlapping events with single peaks were used to create an ensemble average mIPSC. A mean weighted decay time constant was determined from biexponential fitting function I(t) ϭ A 1 ϫ e (Ϫt / 1) ϩ A 2 ϫ e (Ϫt / 2) as w ϭ (A 1 ϫ 1 ϩ A 2 ϫ 2 )/(A 1 ϩ A 2 ). For each electrophysiology experiment, 2-4 animals were used per group.
Hippocampus kindling model of epilepsy. Seizure experiments were conducted using hippocampus kindling model (Reddy and Mohan, 2011; Reddy et al., 2015) . Mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). A bipolar electrode fixed to a guide cannula (Plastics One) was stereotaxically implanted in the right ventral hippocampus (2.9 mm posterior, 3.0 mm lateral, and 3.0 mm below dura). After postoperative recovery, animals were subjected to kindling stimulation (Reddy and Mohan, 2011) . The electrographic afterdischarge (AD) threshold was determined by application of 1 ms biphasic rectangular pulses at 60 Hz for 1 s, in increments of 25 A using an isolated pulse stimulator (A-M Systems). AD duration was the total duration of electrographic spike activity (amplitude Ͼ2ϫ baseline) occurring in a rhythmic pattern at a frequency Ͼ1 Hz. Mice were stimulated at 125% AD threshold once per day until Stage 5 seizures were elicited on 3 consecutive days, considered the fully kindled state. The electrographic activity was recorded using Axoscope 8.0 software with Digidata 1322A interface (Molecular Devices) through a Grass CP511 preamplifier (Astro-Med). Behavioral seizures were rated according to Racine's scale as modified for mouse. One week after kindling, ZnCl 2 (10 -1000 M) was dissolved in sterile saline and microinfused in 5 l volume directly into the hippocampus using a perfusion pump at 0.2 l/min. Mice were monitored for seizures and electrographic activity for at least 10 min. AP (s.c.) was administered 15 min before or after infusion of Zn 2ϩ . AP was dissolved in 20% ␤-cyclodextrin solution for subcutaneous injections. After each stimulation, mice were scored for protection based on the behavioral motor seizures and AD duration.
Drugs and reagents. All chemicals were purchased from Sigma-Aldrich unless otherwise specified. Drug solutions for slice recording were prepared as 2 mM stock solution in DMSO. They were diluted in the external perfusion solution to the desired concentration for electrophysiological use. DMSO concentration in final solution was Ͻ1%. AP was acquired from Steraloids. Kynurenic acid was acquired from Tocris Bioscience. TTX was acquired from Calbiochem.
Statistical analysis. Group data are expressed as mean Ϯ SEM. Statistical comparisons of parametric measures, including electrophysiology data, were performed using an independent two-tailed Student's t test followed by Tukey's HSD test post hoc. Cumulative probability distributions of mIPSCs before and after Zn 2ϩ application were compared with the nonparametric Kolmogorov-Smirnov test. In all statistical tests, the criterion for statistical significance was p Ͻ 0.05, unless otherwise specified.
Results

Neurosteroid AP potentiation of tonic currents is selectively sensitive to negative modulation by Zn
2؉
We recorded neurosteroid-activated tonic currents from DGGCs in the hippocampus slice using whole-cell, voltage-clamp (Ϫ65 mV) electrophysiology (Fig. 1) . We first investigated Zn 2ϩ block of endogenous I tonic from nonpotentiated ␦GABA A receptors. In recordings without exogenous GABA, 50 M Zn 2ϩ produced 0.22 Ϯ 0.03 pA/pF positive shift, 100 M Zn 2ϩ produced 0.26 Ϯ 0.10 pA/pF shift, and 50 M of the competitive antagonist gabazine resulted in 0.53 Ϯ 0.10 pA/pF shift in I tonic (n ϭ 7 cells). This resulted in an overall mean 55.1 Ϯ 0.1% and 58.2 Ϯ 0.2% fractional block of total endogenous I tonic by 50 and 100 M Zn 2ϩ , respectively. To study neurosteroid AP potentiation of a physiological concentration of GABA (Wlodarczyk et al., 2013) , we recorded I tonic at 0.2 M GABA ϩ 0.3 M AP. AP induced negative shift in the holding current level and increased the RMS channel conductance as previously reported (Carver et al., 2014) , but Zn 2ϩ (50 M) application positively shifted AP-dependent I tonic 0.87 Ϯ 0.09 pA/pF (n ϭ 7 cells) (Fig. 1Ai) . To further demonstrate pharmacological sensitivity of Zn 2ϩ block of AP potentiation, 1 M GABA ϩ 0.3 M AP effect on current was recorded. Subsequent application of Zn 2ϩ (0.1-1000 M) resulted in concentration-dependent block of I tonic , measured as positive shift in the holding current level (Fig. 1Aii) . Zn 2ϩ wash-out rapidly reversed the I tonic to the previously enhanced level by AP (Fig.  1Aiii) . Zn 2ϩ -induced block of AP-sensitive I tonic is summarized in Figure 1B . Gabazine block of the AP-modulated I tonic response was significantly greater than fractional block by Zn 2ϩ at 1-100 M, but not at 1000 M (Fig. 1C) . The IC 50 value of Zn 2ϩ blockade of tonic current was 16.3 Ϯ 5.8 M. Zn 2ϩ significantly reduced the I RMS channel conductance of AP modulation ranging from 7.8 Ϯ 2.3% reduction in 1 M Zn 2ϩ ( p ϭ 0.0095) to 30.0 Ϯ 4.2% in 1000 M Zn 2ϩ ( p ϭ 0.0003) (Fig. 1D ). In DGGCs from ␦GABA A receptor knock-out mice, Zn 2ϩ application had no significant effect on I tonic (Fig. 1 E, F ) .
Neurosteroid AP potentiation of phasic currents is insensitive to negative allosteric modulation by Zn
2؉
We investigated the effect of Zn 2ϩ on AP-activated postsynaptic phasic currents in DGGCs (Fig. 2) (Mangan et al., 2005) . Therefore, we analyzed mIPSC events (in the presence of TTX) before and during 10 or 100 M Zn 2ϩ modulation of GABA A receptors. AP (0.3 M) significantly increased the weighted decay time constant ( w ) and peak amplitude of mIPSCs from DGGCs (Fig. 2) . We did not observe Zn 2ϩ depression of AP-modulated mIPSC weighted decay time constant ( Fig. 2 B, C) , and mean and cumulative distribution amplitudes were not significantly different (Fig. 2D) . These findings indicate that Zn 2ϩ -induced blockade of AP-mediated GABAergic current in DGGCs is highly selective for extrasynaptic ␦GABA A receptors, which mediate the majority of tonic inhibition (ϳ95%) in DGGCs. membrane-permeable, high-affinity Zn 2ϩ chelator (Gordey et al., 1995; Meeusen et al., 2012) . Zn 2ϩ (50 M) blocked I tonic of DGGCs perfused with 0.2 M GABA ϩ 0.3 M AP, resulting in a positive shift of current 0.87 Ϯ 0.09 pA/pF. Such Zn 2ϩ block was prevented when 100 M TPEN was added to the perfusion, and DGGCs displayed Ϫ0.57 Ϯ 0.16 pA/pF negative shift in I tonic (Fig. 3B) . The difference between Zn 2ϩ -antagonized and TPEN-enhanced I tonic was statistically significant (p Ͻ 0.001, n ϭ 7-8 cells per group) (Fig. 3B) . Without Zn 2ϩ added to perfusion, TPEN sustained negative shift of the AP-modulated I tonic Ϫ0.52 Ϯ 0.07 pA/pF (n ϭ 7 cells) (Fig. 3A) , indicating significant modulation of endogenous Zn 2ϩ within the brain slice. The Zn 2ϩ chelating effect by TPEN was also demonstrated in an alternative protocol, where Zn 2ϩ was added to the slice immediately after TPEN (Fig. 3C) .
Zn
2؉ elicits epileptiform seizures and inhibits the antiseizure effect of the neurosteroid AP in the kindling model of epilepsy To directly examine the effect of Zn 2ϩ on hippocampus hyperexcitability and seizures in epileptic animals, we generated fully kindled mice that exhibit consistent, Stage 5 (generalized) seizures. We then tested whether intrahippocampal Zn 2ϩ (10 -1000 M) infusion promotes seizure susceptibility in fully kindled, epileptic mice before and after AP treatment (Fig. 4Ai) . The percentage of animals experiencing seizures was dose-dependent, with a smaller percentage of animals experienced generalized seizures due to either 10 or 100 M Zn 2ϩ compared with 1000 M infusion (Fig. 4B) . High-dose Zn (Fig. 4C,E) and significant protection from kindling seizures (Fig. 4D) . Despite AP treatment, 100 -1000 M Zn 2ϩ -infused mice exhibited significantly greater AD durations and higher incidence of seizures. After 24 h washout of drug, electric stimulation resulted in the return of Stage 5 seizures in all animals, indicating the reversible effect of Zn 2ϩ on kindling seizures. The 1000 M Zn 2ϩ infusion elicited seizures in 100% of animals and was used to test pretreatment with AP (1-10 mg/kg, s.c.) (Fig. 4Aii) . AP-treated mice displayed dosedependent protection against Zn 2ϩ -induced seizures (Fig. 4B) . Collectively, these results indicate that Zn 2ϩ may play an important role in the modulation of seizures by anticonvulsant neurosteroids, such as AP, which are powerful activators of ␦GABA A receptors.
Discussion
Zn 2؉ selectively inhibits extrasynaptic ␦GABA A receptormediated tonic inhibition in the hippocampus This study shows that Zn 2ϩ is a highly selective negative modulator of neurosteroid-sensitive, extrasynaptic ␦GABA A receptors that are responsible for tonic inhibition in the dentate gyrus, a key limbic region associated with epilepsy and memory disorders. Zn 2ϩ inhibition of neurosteroid seizure protection in epileptic animals is novel. These findings are consistent with a facilitator role for Zn 2ϩ in excitability (Buhl et al., 1996) , excitotoxicity (Choi et al., 1988) , and seizure disorders (Cavazos et al., 1991; Coulter, 2000) . Neurosteroid-positive modulators that target ␦GABA A receptors are being investigated as therapeutic agents for brain diseases (Whissel et al., 2015; Carver and Reddy, 2016) . Neurosteroids have potent anticonvulsant effects in animal models and clinical trials (Reddy, 2011) . Tonic inhibition is vital to control network excitability and seizure susceptibility (Carver et al., 2014) , but physiological interaction of Zn 2ϩ and neurosteroids at GABA A receptors has not been examined previously. We observed potent Zn 2ϩ blockade of neurosteroid-sensitive tonic currents but not phasic currents. A previous study reported inhibition of phasic currents by Zn 2ϩ (Ruiz et al., 2004) ; however, we demonstrate that neurosteroid-mediated GABA A receptor potentiation overcomes Zn 2ϩ depression of synaptic receptors. Because of the high affinity for ␦-containing receptors, Zn 2ϩ and neurosteroids influence inhibition through opposing action, albeit at different allosteric sites (Hosie et al., 2003 function may be quite different from its role in pathological states, such as epilepsy. The overall contribution of Zn 2ϩ to excitability may be dependent on the net responses of inhibitory and excitatory targets. Epileptogenic proliferation of mossy fibers in the dentate gyrus could play a role in augmented Zn 2ϩ release (Coulter, 2000) . Zn 2ϩ depletion has also been implicated in seizure susceptibility (Bitanihirwe and Cunningham, 2009 (Vogt et al., 2000) . Based on our electrophysiology studies, these concentrations are sufficient to block extrasynaptic ␦GABA A receptors (IC 50 ϭ 16 M). In addition, the synaptic levels of Zn 2ϩ may reach as high as 200 -300 M in the hippocampus during seizures (Cavazos et al., 1991; Buhl et al., 1996) , indicating the potential seizure-exacerbating ability of Zn 2ϩ . In our attempt to demonstrate that chelation of endogenous Zn 2ϩ in brain slices with TPEN can enhance tonic current, we observed a small but statistically significant effect of TPEN (Fig. 3B ). In the dentate gyrus, Zn 2ϩ inhibits the GABA A receptor current, as previously observed (Gordey et al., 1995; Ruiz et al., 2004) . By elevation of dietary Zn 2ϩ or conditions in which the blood-brain barrier is disrupted, peripheral Zn 2ϩ could possibly contribute to total levels in the brain, exerting effects to block GABA A receptors. Inhibitory deficits and GABA A receptor plasticity resulting from epilepsy may also alter the targets of Zn 2ϩ and neurosteroids (Kapur and Macdonald, 1997; Peng et al., 2004) . Similarly, Cu 2ϩ displays ␦-containing receptor selectivity, and excessive levels in Wilson's disease could decrease tonic inhibition (McGee et al., 2013) , suggesting a pathophysiological shift in excitability.
Zn
2؉ promotes epileptiform seizures and antagonizes neurosteroid seizure protection We sought to understand how Zn 2ϩ affects seizure susceptibility in epilepsy. Microinfusion of Zn 2ϩ directly into the hippocampus rapidly caused epileptiform discharges and generalized seizures in fully kindled mice. This is consistent with Zn 2ϩ blockade of GABA A receptors, leading to hyperexcitability and epileptiform seizures originating within the hippocampus (Slevin et al., 1986) , but contrary to an earlier report (Elsas et al., 2009 ). Our findings indicate that pretreatment with the neurosteroid AP blocks such proconvulsant actions triggered by Zn 2ϩ . Similarly, Zn 2ϩ blocks the antiseizure effects of systemically administered AP in fully kindled mice. These results are consistent with pharmacological antagonistic features of Zn 2ϩ at extrasynaptic ␦GABA A receptors. It remains unclear whether the observed in vivo augmentation of seizure susceptibility is the result of Zn 2ϩ -mediated inhibition of AP-induced tonic currents in DGGCs. Zn 2ϩ also blocks ␣ 4 ␤␥-and ␣ 1 ␤␦-containing GABA A receptors, albeit at lower sensitivities than ␣ 4 ␤␦ isoforms (Brown et al., 2002) . Specific ␦-subunit knock-out of DG interneurons decreases tonic inhibition and increases firing frequency that leads to decreased DGGC excitability and lower in vivo seizure susceptibility (Lee and Maguire, 2013) . Thus, the effect of GABAergic block by Zn 2ϩ may result in the disinhibition of ␣ 1 ␤␦-containing interneurons; however, we observed the net outcome of Zn 2ϩ hippocampal infusion to be rapidly increased seizure activity. We have previously shown that ␦GABA A receptor knock-out mice lacking DGGC tonic current have greater seizure susceptibility, suggesting a key role for tonic inhibition in epilepsy (Carver et al., 2014).
In conclusion, these results provide strong evidence that Zn 2ϩ selectively inhibits neurosteroid-sensitive tonic current in may represent a powerful tool to study the neurophysiology of extrasynaptic GABA A receptors and their modulation by endogenous neurosteroids (Villumsen et al., 2015) . These results underscore the potential role of Zn 2ϩ in modulating GABAergic tonic inhibition. Together, these findings have pathophysiological implications in many brain hyperexcitability conditions, such as seizures, epileptogenesis, and epilepsy and conditions with compromised neurovascular unit or Zn 2ϩ transport pathways in the brain.
